Medicare Compliance & Reimbursement - 2003 Issue 33
Pharmaceuticals: DRUG REBATES STILL RAISING EYEBROWS WITH THE FEDS
Subscribe or sign in to view the full article.
Article Overview
This article discusses ongoing federal scrutiny of Medicaid drug rebate accounting, including how the HHS Office of Inspector General reviews state records and compares rebate collection practices across multiple states and Washington, DC. It is relevant to pharmaceutical manufacturers, compliance professionals, and anyone tracking Medicaid rebate oversight, fraud risk, and state agency administration of drug rebate programs.
Why This Topic Matters
The topic matters because rebate compliance remains a significant federal enforcement issue for manufacturers and state Medicaid agencies, with potential financial and legal exposure tied to audit findings and settlement risk.
What You Will Learn
- How federal oversight is being applied to Medicaid drug rebate accounting
- Which kinds of state review results are discussed in relation to rebate compliance
- Why drug rebate administration remains an ongoing compliance concern for manufacturers
- How HHS OIG review activity informs Medicaid rebate enforcement focus
Who Should Read This
- Pharmaceutical manufacturers
- Compliance professionals
- Medicaid administrators
- Healthcare auditors
- Healthcare attorneys
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com